

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Docket Number: PUR-00114.P.1.1	Application Number: 09/832,621
Applicant: Raucy	,

Group Art Unit: 1634

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
MBS	P1	5,071,773	12/10/91	Evans et al.	-	ĺ	
	P2	5,298,429	3/29/94	Evans et al.	<u> </u>		
	P3	5,639,616	6/17/97	Liao et al.			
	P4	2002/022599	2/21/02	Synold et al.	_		
	P5	2002/0150915	10/17/02	Berkenstam et al.	_		
	P6	2002/0168623	11/14/02	Raucy		~.	
	P7	2003/0064430	4/03/03	Evans et al.	_		

Filing Date: April 11, 2001

Signature Considered	Date Considered	_			X	I Q	Zi	K	Examiner	
----------------------	-----------------	---	--	--	---	-----	----	---	----------	--



•		FORE	IGN PATE	NT DOCUME	NTS			
EXAMINER		DOCUMENT	DATE	COUNTRY	CLASS	SUB-	Translation	
INITIAL		NUMBER				CLASS	YES	NO
MBS	F1	EP 0 644 267 A2	7/20/94	ЕРО				
	F2	WO 88/03168	5/5/88	PCT	_			
	F3	WO 94/27557	12/8/94	PCT				
	F4	WO 99/61622	12/2/99	PCT				
	F5	WO 01/20026 A2	3/22/01	PCT		<u> </u>		
	F6	WO 01/71361 A1	9/27/01	PCT				
	F7	WO 01/97856 A2	12/27/01	PCT				
	F8	WO 02/24918 A1	3/28/02	PCT				
	F9	WO 02/36784 A1	5/10/02	PCT	_			
	F10	WO 02/088305 A2	11/7/02	PCT				
	F11	WO 02/094865 A1	11/28/02	PCT				
	F12	WO 02/095652 A1	11/28/02	PCT				

Examiner Signature	122	Date Considered	

		107 g 3 2003 g				
	ALEX.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
EXAMINER INITIALS		CHATION				
MS	D1	Barwick, Mol. Pharmacol., 50:10-16 (1996).				
	D2	Dogra et al., Clinical Pharmacology and Physiology, 25: 1-9 (1998).				
	D3	Chen et al., Mol. Pharmacol., 64:316-324 (2003).				
	D4	Cui et al., Journal of Pharmacology and Toxicological Methods, 47: 143-151 (2002).				
	D5	Ferguson et al., Mol. Pharmacol. 62(3): 737-746 (2002).				
	D6	Gonzalez et al., DNA, 7(2): 79-86 (1988).				
	D7	Hakkola et al., Critical Reviews in Toxicology, 28(1): 35-72 (1998)				
	D8	Hashimoto et al., Eur. J. Biochem., 218: 585-595 (1993).				
	D9	Honkakoski et al., Ann. Med. 35(3): 172-182 (2003).				
	D10	Kliewer et al., Cell, 92:73-82 (1998).				
	D11	Kolars et al., Pharmacogenetics 4: 247-259 (1994).				
	D12	Kovaleva et al., Biochemical and Biophysical. Research Communications 221: 129-132 (1996).				
	D13	Moore et al., Molecular Endocrinology 16(5):977-986 (2002).				
	D14	Ogg et al., Eur. J. of Drug Metabolism and Pharmacokinetics 22(4): 311-313 (1997).				
	D15	Sakai and Takigami, Ind. Health 41: 205-214 (2003).				
	D16	Smith et al., Xenobiotica, 28(12): 1129-1165 (1998).				
	D17	Sonoda et al., Proc. Natl. Acad. Sci USA 99(21): 13801-13806 (2002).				
	D18	Sulston and Waterston, Genome Res., 8(11): 1097-1108 (1998).				
	D19	Xie et al., Proc Natl. Acad. Sci. USA 100(7): 4150-4155 (2003).				
	D20	Yanagida et al., Molecular and Cellular Biology, 10(4): 1470-1475 (1990).				
	D21	Yueh et al., J of Biological Chemistry 278(17): 15001-15006 (2003).				

Examiner Signature	PR .	Date Considered